Blockade of the kallikrein-kinin system reduces endothelial complement activation in vascular inflammation. 2019

Ingrid Lopatko Fagerström, and Anne-Lie Ståhl, and Maria Mossberg, and Ramesh Tati, and Ann-Charlotte Kristoffersson, and Robin Kahn, and Jean-Loup Bascands, and Julie Klein, and Joost P Schanstra, and Mårten Segelmark, and Diana Karpman
Department of Pediatrics, Clinical Sciences Lund, Lund University, Lund, Sweden.

BACKGROUND The complement and kallikrein-kinin systems (KKS) are activated during vascular inflammation. The aim of this study was to investigate if blockade of the KKS can affect complement activation on the endothelium during inflammation. METHODS Complement deposition on endothelial microvesicles was assayed in vasculitis patient plasma samples and controls. Plasma was perfused over glomerular endothelial cells and complement deposition assayed by flow cytometry. The effect of the kinin system was assessed using kinin receptor antagonists and C1-inhibitor. The in vivo effect was assessed in kidney sections from mice with nephrotoxic serum-induced glomerulonephritis treated with a kinin receptor antagonist. RESULTS Vasculitis patient plasma had significantly more C3- and C9-positive endothelial microvesicles than controls. Perfusion of patient acute-phase plasma samples over glomerular endothelial cells induced the release of significantly more complement-positive microvesicles, in comparison to remission or control plasma. Complement activation on endothelial microvesicles was reduced by kinin B1- and B2-receptor antagonists or by C1-inhibitor (the main inhibitor of the classical pathway and the KKS). Likewise, perfusion of glomerular endothelial cells with C1-inhibitor-depleted plasma induced the release of complement-positive microvesicles, which was significantly reduced by kinin-receptor antagonists or C1-inhibitor. Mice with nephrotoxic serum-induced glomerulonephritis exhibited significantly reduced glomerular C3 deposition when treated with a B1-receptor antagonist. CONCLUSIONS Excessive complement deposition on the endothelium will promote endothelial injury and the release of endothelial microvesicles. This study demonstrates that blockade of the KKS can reduce complement activation and thereby the inflammatory response on the endothelium. BACKGROUND Full details are provided in the Acknowledgements/Funding section.

UI MeSH Term Description Entries
D007074 Immunoglobulin G The major immunoglobulin isotype class in normal human serum. There are several isotype subclasses of IgG, for example, IgG1, IgG2A, and IgG2B. Gamma Globulin, 7S,IgG,IgG Antibody,Allerglobuline,IgG(T),IgG1,IgG2,IgG2A,IgG2B,IgG3,IgG4,Immunoglobulin GT,Polyglobin,7S Gamma Globulin,Antibody, IgG,GT, Immunoglobulin
D008297 Male Males
D008875 Middle Aged An adult aged 45 - 64 years. Middle Age
D011485 Protein Binding The process in which substances, either endogenous or exogenous, bind to proteins, peptides, enzymes, protein precursors, or allied compounds. Specific protein-binding measures are often used as assays in diagnostic assessments. Plasma Protein Binding Capacity,Binding, Protein
D001920 Bradykinin A nonapeptide messenger that is enzymatically produced from KALLIDIN in the blood where it is a potent but short-lived agent of arteriolar dilation and increased capillary permeability. Bradykinin is also released from MAST CELLS during asthma attacks, from gut walls as a gastrointestinal vasodilator, from damaged tissues as a pain signal, and may be a neurotransmitter. Arg-Pro-Pro-Gly-Phe-Ser-Pro-Phe-Arg,Bradykinin Acetate, (9-D-Arg)-Isomer,Bradykinin Diacetate,Bradykinin Hydrochloride,Bradykinin Triacetate,Bradykinin, (1-D-Arg)-Isomer,Bradykinin, (2-D-Pro)-Isomer,Bradykinin, (2-D-Pro-3-D-Pro-7-D-Pro)-Isomer,Bradykinin, (2-D-Pro-7-D-Pro)-Isomer,Bradykinin, (3-D-Pro)-Isomer,Bradykinin, (3-D-Pro-7-D-Pro)-Isomer,Bradykinin, (5-D-Phe)-Isomer,Bradykinin, (5-D-Phe-8-D-Phe)-Isomer,Bradykinin, (6-D-Ser)-Isomer,Bradykinin, (7-D-Pro)-Isomer,Bradykinin, (8-D-Phe)-Isomer,Bradykinin, (9-D-Arg)-Isomer,Arg Pro Pro Gly Phe Ser Pro Phe Arg
D002478 Cells, Cultured Cells propagated in vitro in special media conducive to their growth. Cultured cells are used to study developmental, morphologic, metabolic, physiologic, and genetic processes, among others. Cultured Cells,Cell, Cultured,Cultured Cell
D003165 Complement System Proteins Serum glycoproteins participating in the host defense mechanism of COMPLEMENT ACTIVATION that creates the COMPLEMENT MEMBRANE ATTACK COMPLEX. Included are glycoproteins in the various pathways of complement activation (CLASSICAL COMPLEMENT PATHWAY; ALTERNATIVE COMPLEMENT PATHWAY; and LECTIN COMPLEMENT PATHWAY). Complement Proteins,Complement,Complement Protein,Hemolytic Complement,Complement, Hemolytic,Protein, Complement,Proteins, Complement,Proteins, Complement System
D003167 Complement Activation The sequential activation of serum COMPLEMENT PROTEINS to create the COMPLEMENT MEMBRANE ATTACK COMPLEX. Factors initiating complement activation include ANTIGEN-ANTIBODY COMPLEXES, microbial ANTIGENS, or cell surface POLYSACCHARIDES. Activation, Complement,Activations, Complement,Complement Activations
D004195 Disease Models, Animal Naturally-occurring or experimentally-induced animal diseases with pathological processes analogous to human diseases. Animal Disease Model,Animal Disease Models,Disease Model, Animal
D004730 Endothelium, Vascular Single pavement layer of cells which line the luminal surface of the entire vascular system and regulate the transport of macromolecules and blood components. Capillary Endothelium,Vascular Endothelium,Capillary Endotheliums,Endothelium, Capillary,Endotheliums, Capillary,Endotheliums, Vascular,Vascular Endotheliums

Related Publications

Ingrid Lopatko Fagerström, and Anne-Lie Ståhl, and Maria Mossberg, and Ramesh Tati, and Ann-Charlotte Kristoffersson, and Robin Kahn, and Jean-Loup Bascands, and Julie Klein, and Joost P Schanstra, and Mårten Segelmark, and Diana Karpman
January 1989, Advances in experimental medicine and biology,
Ingrid Lopatko Fagerström, and Anne-Lie Ståhl, and Maria Mossberg, and Ramesh Tati, and Ann-Charlotte Kristoffersson, and Robin Kahn, and Jean-Loup Bascands, and Julie Klein, and Joost P Schanstra, and Mårten Segelmark, and Diana Karpman
January 1999, Proceedings of the Association of American Physicians,
Ingrid Lopatko Fagerström, and Anne-Lie Ståhl, and Maria Mossberg, and Ramesh Tati, and Ann-Charlotte Kristoffersson, and Robin Kahn, and Jean-Loup Bascands, and Julie Klein, and Joost P Schanstra, and Mårten Segelmark, and Diana Karpman
September 1999, Immunopharmacology,
Ingrid Lopatko Fagerström, and Anne-Lie Ståhl, and Maria Mossberg, and Ramesh Tati, and Ann-Charlotte Kristoffersson, and Robin Kahn, and Jean-Loup Bascands, and Julie Klein, and Joost P Schanstra, and Mårten Segelmark, and Diana Karpman
June 1989, Agents and actions,
Ingrid Lopatko Fagerström, and Anne-Lie Ståhl, and Maria Mossberg, and Ramesh Tati, and Ann-Charlotte Kristoffersson, and Robin Kahn, and Jean-Loup Bascands, and Julie Klein, and Joost P Schanstra, and Mårten Segelmark, and Diana Karpman
March 2005, The Journal of clinical investigation,
Ingrid Lopatko Fagerström, and Anne-Lie Ståhl, and Maria Mossberg, and Ramesh Tati, and Ann-Charlotte Kristoffersson, and Robin Kahn, and Jean-Loup Bascands, and Julie Klein, and Joost P Schanstra, and Mårten Segelmark, and Diana Karpman
December 2005, FASEB journal : official publication of the Federation of American Societies for Experimental Biology,
Ingrid Lopatko Fagerström, and Anne-Lie Ståhl, and Maria Mossberg, and Ramesh Tati, and Ann-Charlotte Kristoffersson, and Robin Kahn, and Jean-Loup Bascands, and Julie Klein, and Joost P Schanstra, and Mårten Segelmark, and Diana Karpman
November 1984, Zeitschrift fur die gesamte innere Medizin und ihre Grenzgebiete,
Ingrid Lopatko Fagerström, and Anne-Lie Ståhl, and Maria Mossberg, and Ramesh Tati, and Ann-Charlotte Kristoffersson, and Robin Kahn, and Jean-Loup Bascands, and Julie Klein, and Joost P Schanstra, and Mårten Segelmark, and Diana Karpman
October 2002, Journal of the neurological sciences,
Ingrid Lopatko Fagerström, and Anne-Lie Ståhl, and Maria Mossberg, and Ramesh Tati, and Ann-Charlotte Kristoffersson, and Robin Kahn, and Jean-Loup Bascands, and Julie Klein, and Joost P Schanstra, and Mårten Segelmark, and Diana Karpman
January 1979, Acta chirurgica Scandinavica. Supplementum,
Ingrid Lopatko Fagerström, and Anne-Lie Ståhl, and Maria Mossberg, and Ramesh Tati, and Ann-Charlotte Kristoffersson, and Robin Kahn, and Jean-Loup Bascands, and Julie Klein, and Joost P Schanstra, and Mårten Segelmark, and Diana Karpman
July 1999, The Journal of urology,
Copied contents to your clipboard!